title: Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.
abstract: In a retrospective study a new lipid-based delivery system for administration of amphotericin B was evaluated in 26 treatment courses in 22 patients. Amphotericin B was given by infusion diluted in either the lipid solution (1 mg/kg/d; 13 courses) or dextrose (0.92 mg/kg/d; 13 courses). No differences were noted in the serum pharmacokinetics. Fever or rigors were observed in 6 of 13 courses in the conventional amphotericin B group versus none in the lipid amphotericin B group (p = 0.007). Four of 13 courses of treatment were discontinued due to adverse effects in the conventional amphotericin B group compared to none in the other group (p = 0.048). In the lipid amphotericin B group the decrease in creatinine clearance was significantly lower on the fourth day of treatment (p = 0.04) and significantly fewer patients had a decrease of more than 25% in creatinine clearance on the sixth day (4/12 vs 9/11 p = 0.02). These preliminary findings suggest that this lipid amphotericin B formulation is well tolerated with few nephrotoxic effects.
authors.affiliation: Service d'Hématologie Clinique, Hôpital du Bocage, Centre Hospitalier et Universitaire, Dijon, France.
authors.forename: D
authors.initials: D
authors.lastname: Caillot
authors.forename: P
authors.initials: P
authors.lastname: Chavanet
authors.forename: O
authors.initials: O
authors.lastname: Casasnovas
authors.forename: E
authors.initials: E
authors.lastname: Solary
authors.forename: G
authors.initials: G
authors.lastname: Zanetta
authors.forename: M
authors.initials: M
authors.lastname: Buisson
authors.forename: O
authors.initials: O
authors.lastname: Wagner
authors.forename: B
authors.initials: B
authors.lastname: Cuisenier
authors.forename: A
authors.initials: A
authors.lastname: Bonnin
authors.forename: P
authors.initials: P
authors.lastname: Camerlynck
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D003404:Creatinine / Q000097:blood; D016503:Drug Delivery Systems; D005217:Fat Emulsions, Intravenous; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D005217:Fat Emulsions, Intravenous; D000666:Amphotericin B; D003404:Creatinine